Microwave assisted synthesis of 2,5-distyryl-1,3,4-oxadiazole derivatives as anti microbial agents

Dipti L. Namera, Jaynt B. Rathod, Rupali H. Maheta, Umed C. Bhoya*
Chemical Research Laboratory, Department of Chemistry, Saurashtra University, Rajkot - 360005, Gujrat, India
*E-mail address: drucbhoya@gmail.com

ABSTRACT
A new series of 2,5-distyryl-1,3,4-oxadiazole derivatives have been synthesized from cinnamic hydrazide on reaction with various cinnamic acid derivatives. The structures of synthesized compounds have been elucidated by spectral studies like IR, 1HNMR, Mass and also Elemental Analysis. Furthermore, all synthesized compounds were screened for in vitro anti microbial activity against the gram positive (Staphylococcus aureus, Pseudomonas aeruginosa) and gram negative (Escherichia coli) bacterial strain. In which some the compounds show potential inhibition against the test organisms.

Keywords: Substituted cinnamic acid; Substituted 1,3,4-oxadiazoles; antimicrobial activity

1. INTRODUCTION

Oxadiazole exists in different isomeric form such as 1,2,4; 1,2,3; 1,2,5 and 1,3,4. Particularly 1,3,4-oxadiazole ring was thermally stable and have played an important role in medicinal chemistry. They are building blocks for the synthesis of biologically active scaffold. Various remarkable biological activity of 1,3,4-oxadiazoles derivative were reported in literature such as antimicrobial [1-3], antifungal [4,5], anticonvulsant [6], Monoamine oxidase inhibitor [7] and anti-proliferative [8], Hypoglycemic [9] and also they are very good bio isosteres of esters and amides, which can contribute significantly in increasing pharmacological activity by in hydrogen bonding interaction with the receptors [10]. B. Narayana and et al have reported synthesis via modified Fischer Indole method and the anti-inflammatory activity [11]. The synthetic adaptability of 1,3,4-oxadiazole has led to the wide-ranging use of this compound in organic synthesis and have attracted the researcher to work on this type of scaffold and study their biological application.

On the other hand, derivatives of cinnamic acid are important intermediate in organic synthesis and also posses wide range of activity such as antimicrobial [12], anti allergic [13], antitubulin [14], anticancer [15], antioxidant [16,17]. Using the cinnamic hydrazide and triethyl orthoester, microwave assisted synthesis of styril-1,3,4-oxadiazoles have been reported by Kudelko and Zieliski [18-24].

Therefore, considering that the cinnamic acid derivatives and 1,3,4-oxadiazole are important building blocks for the development of new series of heterocycles for
pharmacological interest, we have embarked upon development of various new 1,3,4-oxadiazole derivatives which have been described in following sections.

2. EXPERIMENTAL

Melting points of the synthesized compounds were taken in open capillaries tubes. The purity of the compounds was checked by thin layer chromatography (TLC). The IR spectra were recorded on a Perkin-Elmer 1800 FTIR spectrometer in KBr pellets. The $^1$H NMR spectra were recorded in DMSO-$d_6$ solutions on a Bruker Avance Ultra shielded 400 MHz NMR spectrometer using TMS as the internal standard. The mass spectra were recorded on a Shimadzu GCMS-QP 1000 EX. Elemental analysis of all the synthesized compounds were carried out in Euro EA 3000 Elemental Analyzer and the results are in agreement with the structures assigned. The necessary chemicals were purchased from Spectrochem, Sisco, Loba Chemie, and Sigma Aldrich.

Substituted aromatic aldehyde (10 m mol), malonic acid (15 m mol), piperidine (4 m mol) and pyridine as solvent were taken in 100 ml two necked round bottom flask and refluxed for 6 hours. After the completion the reaction, the reaction mixture was allowed to cool ambient temperature and it was poured on to the mixture of 1:1 HCl: cold water. The separated product was filtered and washed with diluted HCl and crystallized from methanol. The product was enough pure and taken for next step without further purification. Yield 75 % to 88 %.

Cinnamic acid (0.1 mol) was taken in dried 250 ml RBF and cooled it to 0-5 ºC then thionyle chloride (12 ml) was added drop wise with the time period of 40 minute and stirred for 1 hour. Excess thionyle chloride was distilled off under reduced pressure and then added hydrazine hydrate (0.1 mol). After the addition of hydrazine hydrate, reaction mixture was stirred at ambient temperature for 2 hour. The progress and the completion of the reaction were checked by thin layer chromatography. After completion of reaction, reaction mass was poured on to the crushed ice, filtered separated product and washed with cold water. Product was crystallized from glacial CH$_3$COOH. M.P. 116-118 ºC, Yield was 89 %.

2. 1. General procedure for the synthesis of 2-((E)-substituted styryl)-5-((E)-styryl-1,3,4-oxadiazole: (5a-5o).

In dried 100 ml round bottom flask, compound 4a (cinnamohydrazide 10 mmol), substituted cinnamic acid (10 mmol) and POCl$_3$ (15 mmol) were taken and subjected to irradiated under microwave (600 watts) for 5 to 10 minutes under the inert condition. The reaction mixture was cooled to ambient temperature and then poured on to crush ice, stirred for 30 minutes at room temperature and filtered. The obtained solids were further neutralized with 50 ml 10 % sodium bicarbonate solution and wash with 50 ml demineralized water. The resulting compound was purified by column chromatography by silica gel 230-400 mesh using ethyl acetate: hexane (4: 6 v/v) as eluent. Yield: 75-89 %. Physical constants of newly synthesized 2-((E)-substituted styryl)-5-((E)-styryl-1,3,4-oxadiazole derivatives 5a-5o are recorded in Table 1.
Table 1. Physical data of compounds (5a-5o).

| Code | Substitution | Microwave Method | M.P. °C |
|------|--------------|------------------|---------|
|      | R | R_1 | Time (min) | Yield % |         |
| 5a   | H | H  | 4           | 87      | 162-164 |
| 5b   | 2,4-OCH_3 | H  | 6           | 79      | 158-160 |
| 5c   | 4-NO_2 | H  | 7           | 89      | 240-242 |
| 5d   | 4-OC_2H_5 | H | 9           | 80      | 152-154 |
| 5e   | 4-OC_8H_15 | H | 7           | 78      | 132-130 |
| 5f   | 4-F | H  | 8           | 84      | 166-168 |
| 5g   | 4-OH | H  | 10          | 75      | 198-200 |
| 5h   | 4-Cl | H  | 6           | 85      | 162-164 |
| 5i   | 2,5-OCH_3 | H | 6           | 78      | 156-158 |
| 5j   | 2-NO_2 | H  | 6           | 82      | 258-260 |
| 5k   | 4-OC_4H_9 | H | 7           | 83      | 142-144 |
| 5l   | 4-CH_3 | H  | 12          | 85      | 158-160 |
| 5m   | 3,4,5-OCH_3 | H | 11          | 76      | 146-148 |
| 5n   | 3-OCH_3, 4-OH | H | 9           | 89      | 168-170 |
| 5o   | 2-F | H  | 8           | 87      | 176-178 |
2. 2. Analytical data

2. 5-di((E)-styryl)-1,3,4-oxadiazole (5a)

MP: 162-164 °C; IR (cm⁻¹): 3045 (Ar–H stretch), 1680 (C=N stretch of 1,3,4-oxadiazole ring), 2145 (C=C stretching), 1250 (C–O–C stretch of 1,3,4-oxadiazole ring); MS: m/z = 274; ¹H NMR (CDCl₃) δ ppm: 7.05 (2H, d, J = 15.5 Hz), 7.12 (2H, d, J = 15.5 Hz), 7.41-7.52 (10H, m); Elemental Analysis: Calculated for C₁₈H₁₄N₂O; C, 78.81; H, 5.14; N, 10.21; O, 5.83 Found: C, 76.36; H, 6.20; N, 9.17; O, 7.48.

2-((E)-2, 4-dimethoxy styryl)-5-((E)-styryl)-1,3,4-oxadiazole (5b)

MP: 158-160 °C; IR (cm⁻¹): 3052 (Ar–H stretch), 2965(C-H stretch) 1678 (C=N stretch of 1,3,4-oxadiazole ring), 2148 (C=C stretching), 1254 (C–O–C stretch of 1,3,4-oxadiazole ring), 1075 (C–O stretch); MS: m/z = 334; ¹H NMR (CDCl₃) δ ppm: 3.75 (6H, s), 6.98 (1H, d, J = 15.4 Hz), 7.01 (1H, d, J = 15.4 Hz), 6.46 (1H, d, J = 15.8 Hz), 7.17 (1H, d, J = 15.8 Hz), 7.52-7.68 (9H, m); Elemental Analysis: Calculated for C₂₀H₁₈N₂O₃; C, 71.84; H, 5.43; N, 8.38; O, 14.35 Found: C, 70.64; H, 5.33; N, 7.95; O, 16.35.

2-((E)-4-nitrostyryl)-5-((E)-styryl)-1,3,4-oxadiazole (5c)

MP: 240-242 °C; IR (cm⁻¹): 3052 (Ar–H stretch), 1685 (C=N stretch of 1,3,4-oxadiazole ring), 2156 (C=C stretching), 1225 (C–O–C stretch of 1,3,4-oxadiazole ring), 1366 (Assymetric N–O stretch of C–NO₂); MS: m/z = 319; ¹H NMR (CDCl₃) δ ppm: 6.98 (1H, d, J = 15.3 Hz), 6.72 (1H, d, J = 15.3 Hz), 6.92 (1H,d, J = 15.6 Hz), 7.13 (1H, d, J = 15.6 Hz), 7.39-7.47 (5H, m), 7.59-7.67 (4H, d); Elemental Analysis: Calculated for C₁₉H₁₃N₃O₃; C, 67.71; H, 4.10; N, 13.16; O, 15.03 Found: - C, 67.80; H, 4.25; N, 12.96; O, 15.12.

2-((E)-4-ethoxy styryl)-5-((E)-styryl)-1,3,4-oxadiazole (5d)

MP: 152-154 °C; IR (cm⁻¹): 3042 (Ar–H stretch), 2981 (C-H stretch), 1679 (C=N stretch of 1,3,4-oxadiazole ring), 2145 (C=C stretching), 1260 (C–O–C stretch of 1,3,4-oxadiazole ring), 1082 (C–O stretch); MS: m/z = 318; ¹H NMR (CDCl₃) δ ppm: 1.30 (3H, t), 3.89 (2H, q), 6.99 (1H, d, J = 15.1 Hz), 6.71 (1H, d, J = 15.1 Hz), 6.65 (1H, d, J = 15.4 Hz), 7.01 (1H,d, J = 15.4 Hz), 7.95-8.12 (9H, m); Elemental Analysis: Calculated for C₂₀H₁₈N₂O₂; C, 75.45; H, 5.70; N, 8.80; O, 10.05 Found: C, 75.80; H, 4.96; N, 9.00; O, 11.05.

2-((E)-4-(n-octyloxy) styryl)-5-((E)-styryl)-1,3,4-oxadiazole (5e)

MP: 132-130 °C; IR (cm⁻¹): 3062 (Ar–H stretch), 2975 (C-H stretch), 1675 (C=N stretch of 1,3,4-oxadiazole ring), 2150 (C=C stretching), 1250 (C–O–C stretch of 1,3,4-oxadiazole ring), 1080 (C–O stretch); MS: m/z = 400; ¹H NMR (CDCl₃) δ ppm: 1.12 (3H, t), 2.54 (2H, t), 2.60-2.82 (7H, m), 4.22 (2H, d), 7.21 (1H, d, J = 15.2 Hz), 6.98 (1H, d, J = 15.2 Hz), 7.01 (1H, d, J = 15.9 Hz), 7.25 (1H, d, J = 15.9 Hz ), 7.35-7.48 (9H, m); Elemental Analysis: Calculated for C₂₆H₂₆N₂O₂; C, 77.97; H, 7.05; N, 6.99; O, 7.99 Found: C, 76.07; H, 6.12; N, 7.09; O, 8.02.

2-((E)-4-fluorostyryl)-5-((E)-styryl)-1,3,4-oxadiazole (5f)

MP: 166-168 °C; IR (cm⁻¹): 3060 (Ar–H stretch), 1684 (C=N stretch of 1,3,4-oxadiazole ring), 2164 (C=C stretching), 1258 (C–O–C stretch of 1,3,4-oxadiazole ring), 1088 (C–O stretch) 740,1352 (C-F stretch); MS: m/z = 292; ¹H NMR (CDCl₃) δ ppm: 7.0 (1H, d, J = 15.5
Hz), 6.71 (1H, d, J = 15.5 Hz), 6.66 (1H, d, J = 15.1 Hz), 7.14 (1H, d, J = 15.1 Hz), 7.54-7.68 (9H, m); Elemental Analysis: Calculated for C_{18}H_{13}FN_{2}O; C, 73.96; H, 4.48; F, 6.50; N, 9.58; O, 5.47 Found: C, 73.62; H, 5.09; F, 6.25; N, 9.40; O, 6.10.

4-((E)-2-(5-((E)-styryl)-1,3,4-oxadiazol-2-y1vinyl)phenol (5g)

MP: 198-200 °C; IR (cm\(^{-1}\))): 3454 (O-H stretch) 3058 (Ar–H stretch), 1684 (C=N stretch of 1,3,4-oxadiazole ring), 2145 (C=C stretching), 1248 (C–O–C stretch of 1,3,4-oxadiazole ring); MS: m/z = 290; \(^1\)H NMR (CDCl\(_3\)) δ ppm: 6.02 (1H, d, J = 15.3 Hz), 7.04 (1H, d, J = 15.3 Hz), 6.70 (1H, d, J = 15.8 Hz), 6.65 (1H, d, J = 15.7 Hz), 7.06 (1H, d, J = 15.7 Hz), 7.64-7.92 (9H, m); Elemental Analysis: Calculated for C_{18}H_{14}N_{2}O_{2}; C, 74.47; H, 4.86; N, 9.65; O, 11.02 Found: C, 74.11; H, 5.96; N, 9.86; O, 12.08.

2-((E)-4-chlorostyryl)-5-((E)-styryl)-1,3,4-oxadiazole (5h)

MP: 162-164 °C; IR (cm\(^{-1}\))): 3056 (Ar–H stretch), 1685 (C=N stretch of 1,3,4-oxadiazole ring), 2148 (C=C stretching), 1256 (C–O–C stretch of 1,3,4-oxadiazole ring), 552,890 (C-Cl stretch); MS: m/z = 308; \(^1\)H NMR (CDCl\(_3\)) δ ppm: 6.07 (1H, d, J = 15.5 Hz), 7.12 (1H, d, J = 15.5 Hz), 6.75 (1H, d, J = 15.9 Hz), 6.70 (1H, d, J = 15.8 Hz), 7.06 (1H, d, J = 15.7 Hz), 7.74-7.95 (8H, m); Elemental Analysis: Calculated for C_{18}H_{13}ClN_{2}O; C, 70.02; H, 4.24; Cl, 11.48; N, 9.07; O, 5.18 Found: C, 71.00; H, 4.24; Cl, 11.48; N, 9.07; O, 5.18.

2-((E)-2,5-dimethoxystyryl)-5-((E)-styryl)-1,3,4-oxadiazole (5i)

MP: 156-158 °C; IR (cm\(^{-1}\))): 3052 (Ar–H stretch), 2860 (C-H stretch), 1682 (C=N stretch of 1,3,4-oxadiazole ring), 2162 (C=C stretching), 1260 (C–O–C stretch of 1,3,4-oxadiazole ring), 1086 (C–O stretch); MS: m/z = 334; \(^1\)H NMR (CDCl\(_3\)) δ ppm: 3.76 (6H, s), 7.02 (1H, d, J = 15.4 Hz), 6.71 (1H, d, J = 15.4 Hz), 6.51 (1H, d, J = 15.7 Hz), 7.19 (1H, d, J = 15.7 Hz), 7.25 (2H, m), 7.56-7.89 (6H, m); Elemental Analysis: Calculated for C_{20}H_{18}N_{2}O_{3}; C, 71.84; H, 5.43; N, 8.38; O, 14.35 Found: C, 71.65; H, 4.83; N, 8.58; O, 15.20.

2-((E)-2-nitrostyryl)-5-((E)-styryl)-1,3,4-oxadiazole (5j)

MP: 258-260 °C; IR (cm\(^{-1}\))): 3110 (Ar–H stretch), 1678 (C=N stretch of 1,3,4-oxadiazole ring), 2175 (C=C stretching), 1282 (C–O–C stretch of 1,3,4-oxadiazole ring), 1421 (Assymmetric N–O stretch of C–NO\(_2\)); MS: m/z = 319; \(^1\)H NMR (CDCl\(_3\)) δ ppm: 7.60 (1H, d, J = 15.4 Hz), 6.07 (1H, d, J = 15.4 Hz), 6.62 (1H, d, J = 15.9 Hz), 7.54 (1H, d, J = 15.9 Hz), 7.40-7.51 (5H, m), 7.59-7.62 (4H, d); Elemental Analysis: Calculated for C_{19}H_{13}N_{3}O_{5}; C, 67.71; H, 4.10; N, 13.16; O, 15.03 Found: C, 67.92; H, 4.86; N, 12.56; O, 15.88.

2-((E)-4-butoxystyryl)-5-((E)-styryl)-1,3,4-oxadiazole (5k)

MP: 142-144 °C; IR (cm\(^{-1}\))): 3083 (Ar–H stretch), 2946 (C-H stretch), 1688 (C=N stretch of 1,3,4-oxadiazole ring), 2182 (C=C stretching), 1274 (C–O–C stretch of 1,3,4-oxadiazole ring), 1132 (C–O stretch); MS: m/z = 346; \(^1\)H NMR (CDCl\(_3\)) δ ppm: 1.12 (3H, t), 1.48 (2H, q), 1.78 (2H, q), 4.51 (2H, t), 7.00 (1H, d, J = 15.2 Hz), 6.71 (1H, d, J = 15.2 Hz), 6.64 (1H, d, J = 15.9 Hz), 6.99 (1H, d, J = 15.9 Hz), 6.97-7.72 (9H, m); Elemental Analysis: Calculated for C_{22}H_{22}N_{2}O_{2}; C, 76.28; H, 6.40; N, 8.09; O, 9.24 Found: C, 76.37; H, 6.90; N, 8.51; O, 10.16.
2-((E)-4-methylstyryl)-5-((E)-styryl)-1,3,4-oxadiazole (5l)

MP: 158-160 °C; IR (cm⁻¹): 3060 (Ar–H stretch), 2889  (C-H stretch), 1260 (C–O–C stretch of 1,3,4-oxadiazole ring); MS: m/z = 288; ¹H NMR (CDCl₃) δ ppm: 2.10 (3H, s), 7.01 (1H, d, J = 15.1 Hz), 6.72 (1H, d, J = 15.1 Hz), 6.67 (1H, d, J = 15.6 Hz), 7.02(1H, d, J = 15.6 Hz), 7.48-7.56 (9H, m); Elemental Analysis: Calculated for C₁₉H₁₆N₂O; C, 79.14; H, 5.59; N, 9.72; O, 5.55 Found: C, 79.82; H, 4.40; N, 7.12; O, 5.71.

2-((E)-styryl)-5-((E)-3,4,5-trimethoxystyryl)-1,3,4-oxadiazole (5m)

MP: 164-148 °C; IR (cm⁻¹): 3124 (Ar–H stretch), 2966 (C-H stretch), 1645 (C=N stretch of 1,3,4-oxadiazole ring), 1085 (C–O stretch); MS: m/z = 364; ¹H NMR (CDCl₃) δ ppm: 4.12 (9H, s), 7.04 (1H, d, J = 15.3 Hz), 6.72 (1H, d, J = 15.3 Hz), 6.71 (1H, d, J = 15.8 Hz), 7.06 (1H, d, J = 15.8 Hz), 7.64-7.78 (7H, m); Elemental Analysis: Calculated for C₂₁H₂₀N₂O₄; C, 69.22; H, 5.33; N, 7.69; O, 17.56 Found: C, 69.32; H, 5.64; N, 6.29; O, 18.55.

2-methoxy-4-(((E)-2-(5-((E)-styryl)-1,3,4-oxadiazol-2-ylvinyl)phenol (5n)

MP: 168-170 °C; IR (cm⁻¹): 3458 (O-H stretch), 3072 (Ar–H stretch), 2935 (C-H stretch) 1670 (C=N stretch of 1,3,4-oxadiazole ring), 2164 (C=C stretching), 1310 (C–O–C stretch of 1,3,4-oxadiazole ring), 1108 (C–O stretch); MS: m/z = 320; ¹H NMR (CDCl₃) δ ppm: 3.71 (6H, s), 6.998 (1H, d, J = 15.2 Hz), 6.69 (1H, d, J = 15.2 Hz), 6.65 (1H, d, J = 15.9 Hz), 7.00 (1H, d, J = 15.9 Hz), 7.43-7.78 (8H, m); Elemental Analysis: Calculated for C₁₉H₁₆N₂O₃; C, 71.24; H, 5.03; N, 8.74; O, 14.98 Found: C, 72.24; H, 6.05; N, 7.71; O, 13.99.

2-((E)-2-fluorostyryl)-5-((E)-styryl)-1,3,4-oxadiazole (5o)

MP: 176-178 °C; IR (cm⁻¹): 3076 (Ar–H stretch), 1675 (C=N stretch of 1,3,4-oxadiazole ring), 2168 (C=C stretching), 1275 (C–O–C stretch of 1,3,4-oxadiazole ring), 752,1386 (C-Fstretch); MS: m/z = 292; ¹H NMR (CDCl₃) δ ppm: 6.97 (1H, d, J = 15.4 Hz), 6.71 (1H, d, J = 15.4 Hz), 6.57 (1H, d, J = 15.8 Hz), 7.20 (1H, d, J = 15.8 Hz), 7.40-7.68 (9H, m); Elemental Analysis: Calculated for C₁₈H₁₄FN₂O; C, 73.96; H, 4.48; F, 6.50; N, 9.58; O, 5.47 Found: C, 74.76; H, 5.98; F, 5.80; N, 9.71; O, 6.4.

3. Antimicrobial Activity

The all synthesized compounds (5a-o) were screened for in vitro antimicrobial activity against the gram negative bacteria (Escherichia coli) and the gram positive bacteria (Staphylococcus aureus and Bacillus subtilis), expressed plate agar diffusion method.

Comparisons of inhibition zone in bacterial culture by the synthesized compounds were studied by using ofloxacin as a standard drug, at 100 μg/ml concentration. Dimethyl sulphoxide (DMSO) was used to prepare stock and standard solution of compounds (5a-o) and ofloxacin. Bacterial cultures of Bacillus subtilis, Staphylococcus aureus, and Escherichia coli were prepared in the nutrient agar medium. Discs of whatman filter paper (9 cm diameter) were moistened with 100 μg/ml solution of the compounds and discs were carefully placed on bacterial culture plates that had been previously inoculated separately with the microorganism. The bacterial cultures were incubated at 37 °C for 24 hours. The radius of
zone of inhibition (in mm) was observed around the cup after respective incubation was secure and measured in triplicate sets by using a scale.

**Table 2.** Antimicrobial activity of 2,5-distyryl-1,3,4-oxadiazole derivatives (5a-5o).

| Compound code | Zone of inhibition (mm) | Gram Positive | Gram Negative |
|---------------|-------------------------|---------------|---------------|
|               |                         | Staphylococcus aureus | Pseudomonas aeruginosa | Escherichia coli |
| 5a            | 09                      | 08             | 09             |
| 5b            | 10                      | 13             | 11             |
| 5c            | 14                      | 11             | 10             |
| 5d            | 11                      | 14             | 12             |
| 5e            | 13                      | 16             | 13             |
| 5f            | 15                      | 12             | 15             |
| 5g            | 18                      | 10             | 14             |
| 5h            | 20                      | 12             | 16             |
| 5i            | 10                      | 14             | 12             |
| 5j            | 13                      | 11             | 11             |
| 5k            | 13                      | 15             | 12             |
| 5l            | 12                      | 12             | 09             |
| 5m            | 12                      | 14             | 10             |
| 5n            | 18                      | 11             | 14             |
| 5o            | 15                      | 12             | 16             |
| Ofloxacin     | 41                      | 38             | 37             |
| Standard      |                         |                |                |

4. **CONCLUSION**

In present report, we have developed an efficient, simple, rapid and eco-friendly microwave-induced method for preparation of asymmetric 2,5-distyryl-1,3,4-oxadiazole derivatives which give the higher yield and also reduced the reaction time. From the result of biological data, compound 5g, 5h, 5n, showed excellent activity against *Staphylococcus aureus*, while compound 5e and 5k showed maximum bacterial activity against *Pseudomonas aeruginosa*. 


aeruginosa and compound 5o, 5h maximum activity against *Escherichia coli*. Antibacterial activity was compared with ofloxacin as a standard drug. All the compounds were less potent than the standard drugs ofloxacin. The compound having the halogen group shows greater antimicrobial activity.

**ACKNOWLEDGEMENT**

We are thanks to the Department of Chemistry (DST-FIST Funded & UGC-SAP Sponsored), Saurashtra University, Rajkot, for research work. Specially indebted to “National Facility for Drug Discovery through New Chemical Entities (NCE’s), Development & Instrumentation Support to Small Manufacturing Pharma Enterprises”, a programme under Drug & Pharma Research Support (DPRS) jointly funded by Department of Science & Technology New Delhi.

**References**

[1] S. Chao, X. Li, S. Wang, *Huaxue Yanjiu Yu Yingyong*. 22(8) (2010) 1066-1071.
[2] B. Chandrakantha, Prakash Shetty, Vijesh Nambiyar, Nishitha Isloor, Arun M. Isloor, *European Journal of Medicinal Chemistry* 45 (2010) 1206-1210.
[3] Rakesh Kumar, M. Shahar Yar, A. K. Rail, Saurabh Chaturvedi, *Der Pharmacia Lettre* 5 (1) (2013) 366-370.
[4] N. Jain, D. P. Pathak, P. Mishra, S. Jain, *J. Iranian Chem. Soc.* 6 (2009) 77.
[5] L. Srikanth, U. Naik, R. Jadhav, N. Raghunandan, J. Rao, K. Manohar., *Pharma Chemica* 2(4) (2010) 231-243.
[6] M. Bhat, M. Al-Omar, N. Siddiqui, *Pharma Chemica* 2(2) (2010) 1-10.
[7] K. Sushil, V. Gupta, V. Kashaw, P. Mishra, J. Stables, N. Jain., *Med. Chem. Research.* 38(2) (2009) 157-159.
[8] L. Jin, J. Chen, B. Song, Z. Chen, S. Yang, Q. Li, D. Hu, R. Xu, *Bioorg. Med. Chem. Lett.* 16 (2006) 5036.
[9] Wang Bao-Lei, Li Zheng-Ming, Li Yong-Hong, Wang Su-Hua, *Gaodeng Xuexia o Huaxue Xuebao* 29(1) (2008) 90-94.
[10] C. R. W. Guimaraes, D. L. Boger, W. L. Jorgensen, *J. Am. Chem. Soc.* 127 (2005) 17377-17384.
[11] B. Narayana, B. V. Ashalatha,a K. K. Vijaya Raj, J. Fernandes and B. K. Sarojini, *Bioorganic & Medicinal Chemistry* 13 (2005) 4638-4644.
[12] Prateek Sharma, *J. Chem. Pharm. Res.* 3(2) (2005) 403-423
[13] Rolando F. Pellon, Taimirys Mamposo, Erick Godlez, Osmar Calderon, *Synthetic Communications* 30(20) (2000) 3769-3774.
[14] Yin Luo, Ke-Ming Qiu, Xiang Lu, Kai Liu, Jie Fu, Hai-Liang Zhu, *Bioorganic & Medicinal Chemistry* 19(16) (2011) 4730-4738.
[15] Lei Liu, W. Robert Hudgins, Sonsoles Shack, Mu Quan Yin, Dvorit Samid, *International Journal of Cancer* 62(3) (1995) 345-350.
[16] Fausta Natella, Mirella Nardini, Maurizio Di Felice, Cristina Scaccini, *J. Agric. Food Chem.* 47(4) (1999) 1453-1459.

[17] Mario Foti, Mario Piattelli, Maria Tiziana Baratta, Giuseppe Ruberto, *J. Agric. Food Chem.* 44(2) (1996) 497-501.

[18] Kudelko A., Zieliński W., *Tetrahedron Lett.* 53 (2012) 76-77.

[19] Rahul R. Tripathi, Ratnamala P. Sonawane, *International Letters of Chemistry, Physics and Astronomy* 10(2) (2013) 119-125.

[20] Mallikarjun S. Yadawe, Shrishila N. Unki, Sangamesh A. Patil, *International Letters of Chemistry, Physics and Astronomy* 12 (2013) 94-104.

[21] G. Thirunarayanan, *International Letters of Chemistry, Physics and Astronomy* 5 (2014) 89-98.

[22] V. J. Faldu, P. K. Talpara, N. H. Bhuva, P. R. Vachharajani, V. H. Shah, *International Letters of Chemistry, Physics and Astronomy* 6 (2014) 26-32.

[23] Piyush B. Vekariya, Jalpa R. Pandya, Vaishali Goswami, Hitendra S. Joshi, *International Letters of Chemistry, Physics and Astronomy* 7 (2014) 45-52.

[24] R. G. Vaghasiya, H. B. Ghodasara, P. R. Vachharajani, V. H. Shah, *International Letters of Chemistry, Physics and Astronomy* 8 (2014) 30-37.

(Received 21 February 2014; accepted 26 February 2014)